Field Willingham is working to halt the progress of esophageal conditions before they become malignant, using therapies that are minimally invasive.
Hybrid Cancer Drug Could Be Resistance-Resistant
A team of cancer researchers led by scientists at UC San Francisco and Memorial Sloan Kettering Cancer Center demonstrated in human cells and mouse models that a first-of-its-kind hybrid drug can outsmart drug-resistant cancers.
- Unraveling Mechanisms of Drug Resistance in Common Cancer Pathway
- Hybrid Drug Prevents Resistance in Human Cells, Mice